03667nam 2200565 450 991082100060332120200520144314.01-119-06084-21-119-06080-X1-119-06072-9(CKB)4330000000008245(DLC) 2016034128(Au-PeEL)EBL4745624(CaPaEBR)ebr11300198(CaONFJC)MIL978150(PPN)196411955(MiAaPQ)EBC4745624(OCoLC)954037554(EXLCZ)99433000000000824520160715h20172017 uy| 0engurcnu||||||||rdacontentrdamediardacarrierAntibody-drug conjugates fundamentals, drug development, and clinical outcomes to target cancer /edited by Kenneth J. Olivier Jr. and Sara A. HurvitzHoboken, New Jersey :John Wiley & Sons, Incorporated,[2017]©20171 online resource (566 pages) color illustrations1-119-06068-0 Includes bibliographical references and index.Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han.Antibody-toxin conjugatesMonoclonal antibodiesAntineoplastic agentsTumorsTreatmentAntibody-toxin conjugates.Monoclonal antibodies.Antineoplastic agents.TumorsTreatment.615.7/98Olivier Kenneth J.Jr.,1968-Hurvitz Sara A.1970-MiAaPQMiAaPQMiAaPQBOOK9910821000603321Antibody-drug conjugates2231062UNINA